Genmab A/S (GMAB) DCF Valuation

Genmab A/S (GMAB) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Genmab A/S (GMAB) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to evaluate the intrinsic value of Genmab A/S? Our (GMAB) DCF Calculator integrates real-world data with extensive customization features, allowing you to refine your forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 749.4 1,412.1 1,184.6 2,038.4 2,300.8 3,205.4 4,465.6 6,221.2 8,667.1 12,074.6
Revenue Growth, % 0 88.43 -16.11 72.07 12.87 39.32 39.32 39.32 39.32 39.32
EBITDA 387.8 913.8 439.5 983.6 776.7 1,510.2 2,104.0 2,931.2 4,083.5 5,689.0
EBITDA, % 51.75 64.71 37.1 48.26 33.76 47.12 47.12 47.12 47.12 47.12
Depreciation 19.4 34.4 34.9 40.5 33.5 73.2 101.9 142.0 197.9 275.7
Depreciation, % 2.59 2.43 2.95 1.99 1.46 2.28 2.28 2.28 2.28 2.28
EBIT 368.4 879.5 404.6 943.1 743.1 1,437.1 2,002.0 2,789.1 3,885.7 5,413.3
EBIT, % 49.16 62.28 34.15 46.27 32.3 44.83 44.83 44.83 44.83 44.83
Total Cash 1,532.2 2,245.6 2,700.8 3,117.8 3,929.4 3,205.4 4,465.6 6,221.2 8,667.1 12,074.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 417.6 344.0 470.2 797.8 690.9
Account Receivables, % 55.72 24.36 39.7 39.14 30.03
Inventories -1,452.2 -34.8 -4.3 -20.0 8.0 -663.3 -924.0 -1,287.3 -1,793.4 -2,498.5
Inventories, % -193.78 -2.46 -0.36548 -0.97979 0.346 -20.69 -20.69 -20.69 -20.69 -20.69
Accounts Payable .0 20.3 48.9 239.7 .0 111.0 154.7 215.5 300.2 418.2
Accounts Payable, % 0 1.43 4.13 11.76 0 3.46 3.46 3.46 3.46 3.46
Capital Expenditure -15.5 -42.9 -35.2 -44.3 -52.5 -80.3 -111.9 -155.9 -217.2 -302.6
Capital Expenditure, % -2.07 -3.04 -2.97 -2.17 -2.28 -2.51 -2.51 -2.51 -2.51 -2.51
Tax Rate, % 22.8 22.8 22.8 22.8 22.8 22.8 22.8 22.8 22.8 22.8
EBITAT 279.1 708.7 300.4 730.9 573.7 1,107.4 1,542.7 2,149.3 2,994.3 4,171.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 1,317.7 -623.4 172.0 606.1 394.0 1,362.1 1,361.0 1,896.0 2,641.5 3,680.0
WACC, % 8.13 8.15 8.13 8.14 8.14 8.14 8.14 8.14 8.14 8.14
PV UFCF
SUM PV UFCF 8,342.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 3,754
Terminal Value 61,144
Present Terminal Value 41,347
Enterprise Value 49,690
Net Debt -1,969
Equity Value 51,659
Diluted Shares Outstanding, MM 66
Equity Value Per Share 783.72

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
  • Real-World Data: Genmab A/S’s financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
  • Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and streamlining your workflow.

Key Features

  • Customizable Research Parameters: Adjust essential metrics such as drug development timelines, clinical trial costs, and expected market penetration.
  • Instant Valuation Calculations: Provides immediate insights into intrinsic value, NPV, and other financial metrics.
  • High-Precision Accuracy: Leverages Genmab’s actual financial data for reliable valuation results.
  • Effortless Scenario Analysis: Easily evaluate various hypotheses and analyze different outcomes.
  • Efficiency Booster: Removes the necessity of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Genmab A/S’s pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Watch the DCF model update instantly as you adjust your assumptions.
  5. Step 5: Analyze the outputs and leverage the results for investment decisions.

Why Choose Genmab A/S (GMAB)?

  • Innovative Solutions: Cutting-edge therapies that address unmet medical needs.
  • Strong Pipeline: A diverse range of products in various stages of development enhances growth potential.
  • Expert Team: Led by industry leaders with extensive experience in biopharmaceuticals.
  • Commitment to Quality: Rigorous standards ensure the highest level of product integrity.
  • Proven Track Record: Recognized for successful collaborations and partnerships in the biotech sector.

Who Should Use This Product?

  • Investors: Accurately estimate Genmab A/S’s fair value before making investment decisions.
  • CFOs: Leverage a professional-grade DCF model for financial reporting and analysis specific to Genmab A/S (GMAB).
  • Consultants: Quickly adapt the template for valuation reports tailored to Genmab A/S (GMAB) clients.
  • Entrepreneurs: Gain insights into financial modeling practices employed by leading biotech firms like Genmab A/S (GMAB).
  • Educators: Use it as a teaching tool to illustrate valuation methodologies relevant to the biotech industry.

What the Template Contains

  • Pre-Filled DCF Model: Genmab A/S’s financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Genmab A/S’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.